This article discusses a recent study that found a potential link between the frequent use of “Gababin” (Gabapentin) for lower back pain and an increased risk of dementia and moderate cognitive impairment.
Here’s a breakdown of the key points:
The Link: The study suggests that frequent use of Gababin is associated with a higher likelihood of developing dementia and moderate cognitive weakness.
Age Matters: The risks appear to be more pronounced in younger age groups.
While the 18-34 age group showed no increased risk, the 35-49 age group had more than double the risk of dementia and more than triple the risk of mild cognitive impairment.
A similar pattern was observed in the 50-64 age group.
Dose-Response: The risk increases with the number of prescriptions.
Individuals receiving 6 or more prescriptions were 29% more likely to be diagnosed with dementia and 85% more likely to be diagnosed with moderate cognitive weakness within 10 years.
Those receiving 12 or more prescriptions had a 40% higher risk of dementia and a 65% higher risk of moderate cognitive impairment compared to those who received 3-11 prescriptions.
What is Gababin (gabapentin)?
It’s an anti-synthesis or anti-epilepsy drug.
While initially used for epilepsy, its use expanded to treat neurological pain (like pain from herpes, diabetic neuropathy, and restless legs syndrome).
It’s thought to calm nerve activity by affecting calcium channels and reducing the release of excitatory neurotransmitters, helping with pain relief and seizure control. It’s considered a non-opioid option for chronic pain due to a lower addiction potential.
growing Use and Concerns: Gabapentin’s use for chronic pain, especially neurological pain, has increased due to its neuroprotective benefits and lower addiction risk compared to opioids. Though, concerns about side effects, including potential links to nervous degeneration, have been raised, though previous results were mixed.
Study Methodology:
The researchers used electronic health records from 68 US healthcare institutions via the “Trinetx” network.
They analyzed anonymized records of adult patients prescribed Gabapentin for chronic lower back pain between 2004 and 2024.
They compared patients prescribed Gabapentin with a control group who did not receive it (26,414 in each group).
Factors like population composition,accompanying conditions,and the use of other pain relievers were considered.
* Limitations: The researchers acknowledge that the study is observational, meaning it can onyl show correlation, not causation. It was also retrospective, and they were unable to control for all potential factors.
In essence,the study highlights a concerning association between frequent Gabapentin use for lower back pain and an increased risk of cognitive decline,notably in younger and middle-aged adults. This suggests a need for greater caution when prescribing this medication.
